Abstract:Combating influenza is one of the perennial global public health issues to be managed. Antiviral drugs are useful for the treatment of influenza in the absence of an appropriate vaccine. However, the appearance of resistant strains necessitates a constant search for new drugs. In this study, we investigated novel anti-influenza drug candidates using in vitro and in vivo assays. We identified anti-influenza hit compounds using a high-throughput screening method with a green fluorescent protein-tagged recombinant influenza virus. Through subsequent analyses of their cytotoxicity and pharmacokinetic properties, one candidate (IY7640) was selected for further evaluation. In a replication kinetics analysis, IY7640 showed greater inhibitory effects during the early phase of viral infection than the viral neuraminidase inhibitor oseltamivir. In addition, we observed that hemagglutinin (HA)-mediated membrane fusion was inhibited by IY7640 treatment, indicating that the HA stalk region, which is highly conserved across various (sub)types of influenza viruses, may be the molecular target of IY7640. In an escape mutant analysis in cells, amino acid mutations were identified at the HA stalk region of the 2009 pandemic H1N1 (pH1N1) virus. Even though the in vivo efficacy of IY7640 did not reach complete protection in a lethal challenge study in mice, these results suggest that IY7640 has potential to be developed as a new type of anti-influenza drug.IMPORTANCE Anti-influenza drugs with broad-spectrum efficacy against antigenically diverse influenza viruses can be highly useful when no vaccines are available. To develop new anti-influenza drugs, we screened a number of small molecules and identified a strong candidate, IY7640. When added at the time of or after influenza virus infection, IY7640 was observed to successfully inhibit or reduce viral replication in cells. We subsequently discovered that IY7640 targets the stalk region of the influenza HA protein, which exhibits a relatively high degree of amino acid sequence conservation across various (sub)types of influenza viruses. Furthermore, IY7640 was observed to block HA-mediated membrane fusion of H1N1, H3N2, and influenza B viruses in cells. Although it appears less effective against strains other than H1N1 subtype viruses in a challenge study in mice, we suggest that the small molecule IY7640 has potential to be optimized as a new anti-influenza drug.

A cell-based screening system for influenza A viral RNA transcription/replication inhibitors

A Parallel Phenotypic Versus Target-Based Screening Strategy For Rna-Dependent Rna Polymerase Inhibitors Of The Influenza A Virus

Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening.

Establishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and Replication

An Interferon-Beta Promoter Reporter Assay for High Throughput Identification of Compounds Against Multiple RNA Viruses

High-Throughput cell-based immunofluorescence assays against influenza

In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Effective Small Interfering RNAs Targeting Matrix and Nucleocapsid Protein Gene Inhibit Influenza A Virus Replication in Cells and Mice

RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals

Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses

Identification of influenza A nucleoprotein as an antiviral target

Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication

Screening for Novel Small-Molecule Inhibitors Targeting the Assembly of Influenza Virus Polymerase Complex by A Bimolecular Luminescence Complementation-Based Reporter System

Inhibition of Influenza Virus Production in Virus-Infected Mice by RNA Interference.

Viral RNA Polymerase: A Promising Antiviral Target for Influenza A Virus

[Establishment of drug screening assay and pharmacodynamic evaluation method targeting influenza RNA polymerase].

Chemical Intervention of Influenza Virus Mrna Nuclear Export

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures

Inhibition of Influenza a Virus Replication by Antagonism of a PI3K-AKT-mTOR Pathway Member Identified by Gene-Trap Insertional Mutagenesis

Identification of a Novel Inhibitor Targeting Influenza A Virus Group 2 Hemagglutinins.